NASDAQ:PODD Insulet (PODD) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free PODD Stock Alerts $171.68 +5.82 (+3.51%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$164.08▼$173.7650-Day Range$163.60▼$207.5552-Week Range$125.82▼$335.91Volume735,103 shsAverage Volume930,810 shsMarket Capitalization$12.01 billionP/E Ratio59.00Dividend YieldN/APrice Target$250.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Insulet alerts: Email Address Insulet MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.81 Rating ScoreUpside/Downside45.8% Upside$250.33 Price TargetShort InterestHealthy3.83% of Shares Sold ShortDividend StrengthN/ASustainability-1.20Upright™ Environmental ScoreNews Sentiment0.85Based on 18 Articles This WeekInsider TradingSelling Shares$1.89 M Sold Last QuarterProj. Earnings Growth25.65%From $3.08 to $3.87 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.99 out of 5 starsMedical Sector6th out of 947 stocksSurgical & Medical Instruments Industry1st out of 99 stocks 4.4 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $250.33, Insulet has a forecasted upside of 45.8% from its current price of $171.68.Amount of Analyst CoverageInsulet has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.83% of the outstanding shares of Insulet have been sold short.Short Interest Ratio / Days to CoverInsulet has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Insulet has recently decreased by 1.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsulet has received a 80.74% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Insulet is -1.20. Previous Next 3.8 News and Social Media Coverage News SentimentInsulet has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Insulet this week, compared to 8 articles on an average week.Search Interest15 people have searched for PODD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows15 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,891,338.00 in company stock.Percentage Held by InsidersOnly 0.90% of the stock of Insulet is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 25.65% in the coming year, from $3.08 to $3.87 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 59.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 152.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 59.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 225.29.Price to Earnings Growth RatioInsulet has a PEG Ratio of 3.02. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioInsulet has a P/B Ratio of 16.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Insulet Stock (NASDAQ:PODD)Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.Read More PODD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PODD Stock News HeadlinesMarch 8, 2024 | marketbeat.comAre These 5 Undervalued Stocks Ready to Break Out?Albemarle Corp. NYSE: ALB, Ionis Pharmaceuticals Inc. NASDAQ: IONS, Insulet Corp. NASDAQ: PODD, Hess Corp. NYSE: HES and Wynn Resorts Ltd. NASDAQ: WYNN are among undervalued stocks that beat analysts earnings views.March 8, 2024 | marketbeat.comAre These 5 Undervalued Stocks Ready to Break Out? (PODD)Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.March 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.February 23, 2024 | marketbeat.comSprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024Stocks that are trading heavily or have substantial price changes on Friday: Sprouts, Block rise; Booking Holdings, Insulet fallMarch 17, 2024 | finance.yahoo.comPODD Apr 2024 135.000 callMarch 16, 2024 | markets.businessinsider.comInsulet’s Growth Trajectory Affirmed with a Buy Rating and Revised Target PriceMarch 15, 2024 | finance.yahoo.comPODD Apr 2024 165.000 callMarch 15, 2024 | finance.yahoo.comPODD Apr 2024 190.000 putMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 15, 2024 | finance.yahoo.comPODD Jan 2025 180.000 callMarch 14, 2024 | americanbankingnews.comWilliam Blair Comments on Insulet Co.'s Q1 2024 Earnings (NASDAQ:PODD)March 14, 2024 | americanbankingnews.comInsulet Co. to Post Q1 2025 Earnings of $0.62 Per Share, William Blair Forecasts (NASDAQ:PODD)March 11, 2024 | finance.yahoo.comCalculating The Fair Value Of Insulet Corporation (NASDAQ:PODD)March 8, 2024 | finance.yahoo.comInsulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapyMarch 8, 2024 | businesswire.comInsulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump TherapyMarch 7, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD) and Adaptimmune Therapeutics (ADAP)March 5, 2024 | businesswire.comInsulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)March 5, 2024 | businesswire.comInsulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)March 4, 2024 | fool.comIs It Time to Buy the S&P 500's 3 Worst-Performing February Stocks?February 26, 2024 | markets.businessinsider.comInsulet’s Strong Growth and Market Position Justify Buy Rating Despite Short-Term Revenue Guidance ConcernsFebruary 26, 2024 | markets.businessinsider.comBarclays Sticks to Its Hold Rating for Insulet (PODD)February 24, 2024 | finance.yahoo.comInsulet Full Year 2023 Earnings: Beats ExpectationsFebruary 23, 2024 | markets.businessinsider.comAnalyst Scoreboard: 5 Ratings For InsuletFebruary 23, 2024 | finance.yahoo.comInsulet Corporation (NASDAQ:PODD) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Penumbra (PEN), BioMarin Pharmaceutical (BMRN) and Insulet (PODD)February 23, 2024 | finance.yahoo.comQ4 2023 Insulet Corp Earnings CallFebruary 23, 2024 | msn.comInsulet forecasts weak annual revenue growth; shares dropSee More Headlines Receive PODD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/18/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:PODD CUSIP45784P10 CIK1145197 Webwww.insulet.com Phone(978) 600-7000Fax978-600-0120Employees3,000Year Founded2000Price Target and Rating Average Stock Price Target$250.33 High Stock Price Target$350.00 Low Stock Price Target$184.00 Potential Upside/Downside+45.8%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$2.91 Trailing P/E Ratio59.00 Forward P/E Ratio55.74 P/E Growth3.02Net Income$206.30 million Net Margins12.16% Pretax Margin12.65% Return on Equity32.19% Return on Assets7.93% Debt Debt-to-Equity Ratio1.86 Current Ratio3.51 Quick Ratio2.62 Sales & Book Value Annual Sales$1.70 billion Price / Sales7.07 Cash Flow$3.89 per share Price / Cash Flow44.19 Book Value$10.49 per share Price / Book16.37Miscellaneous Outstanding Shares69,930,000Free Float69,297,000Market Cap$12.01 billion OptionableOptionable Beta0.98 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. James R. Hollingshead Ph.D. (Age 61)President, CEO & Director Comp: $2.18MMs. Shacey Petrovic (Age 50)Director & Advisor Comp: $2.96MMr. Eric Benjamin (Age 41)Executive VP, Chief Product & Customer Experience Officer Comp: $947.57kMs. Lauren BuddenGroup VP, Chief Accounting Officer, Controller & Interim CFO and TreasurerMr. Prem Singh (Age 47)Senior Vice President of Global Operations Mr. Mark FieldSenior VP & CTOMs. Deborah R. Gordon CPA (Age 54)Vice President of Investor Relations Mr. John Wodick Kapples (Age 64)Senior VP & General Counsel Comp: $783.36kMs. Laetitia Cousin (Age 48)Senior VP of Regulatory Affairs, Quality Assurance & Compliance Angela Geryak WiczekSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsTeleflexNYSE:TFXAbiomedNASDAQ:ABMDGlobus MedicalNYSE:GMEDBaxter InternationalNYSE:BAXNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsHBK Investments L PBought 7,500 shares on 3/14/2024Ownership: 0.000%Vanguard Group Inc.Bought 29,387 shares on 3/11/2024Ownership: 11.482%SageView Advisory Group LLCBought 1,088 shares on 3/6/2024Ownership: 0.002%Fisher Asset Management LLCSold 59,703 shares on 3/5/2024Ownership: 0.492%Congress Asset Management Co. MABought 15,134 shares on 3/4/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions PODD Stock Analysis - Frequently Asked Questions Should I buy or sell Insulet stock right now? 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PODD shares. View PODD analyst ratings or view top-rated stocks. What is Insulet's stock price target for 2024? 16 brokerages have issued 1 year price objectives for Insulet's shares. Their PODD share price targets range from $184.00 to $350.00. On average, they anticipate the company's share price to reach $250.33 in the next twelve months. This suggests a possible upside of 45.8% from the stock's current price. View analysts price targets for PODD or view top-rated stocks among Wall Street analysts. How have PODD shares performed in 2024? Insulet's stock was trading at $216.98 on January 1st, 2024. Since then, PODD shares have decreased by 20.9% and is now trading at $171.68. View the best growth stocks for 2024 here. When is Insulet's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PODD earnings forecast. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) posted its quarterly earnings data on Thursday, February, 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. The medical instruments supplier earned $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a trailing twelve-month return on equity of 32.19% and a net margin of 12.16%. The company's revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 earnings per share. What ETFs hold Insulet's stock? ETFs with the largest weight of Insulet (NASDAQ:PODD) stock in their portfolio include Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Focused Discovery Growth ETF (IVDG), Harbor Health Care ETF (MEDI), VictoryShares Nasdaq Next 50 ETF (QQQN), Nuveen ESG Mid-Cap Growth ETF (NUMG) and Fidelity Disruptive Medicine ETF (FMED). What guidance has Insulet issued on next quarter's earnings? Insulet updated its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $419.0 million-$429.7 million, compared to the consensus revenue estimate of $442.5 million. What is Shacey Petrovic's approval rating as Insulet's CEO? 61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD). Who are Insulet's major shareholders? Insulet's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital Research Global Investors (13.57%), Vanguard Group Inc. (11.50%), Vanguard Group Inc. (11.48%), Capital World Investors (3.17%), Clearbridge Investments LLC (1.90%) and Baillie Gifford & Co. (1.74%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan. View institutional ownership trends. How do I buy shares of Insulet? Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PODD) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.